863 results on '"A, Masson-Lecomte"'
Search Results
2. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)
3. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
4. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer
5. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure
6. Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients
7. Clinical and pathological features of renal tumours among women previously treated for breast carcinomas – the CanSeRe study
8. Patients non répondeurs au BCG
9. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
10. Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette–Guerin therapy upfront versus a third resection
11. Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification
12. Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma
13. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
14. Principios generales de la cirugía asistida por robot
15. Profil et environnement immunitaires des tumeurs de la voie excrétrice supérieure
16. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures
17. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
18. Chimiothérapie préopératoire des tumeurs des voies excrétrices supérieures : impact sur la fonction rénale
19. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
20. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
21. Inmunoterapia en urología: principios e indicaciones
22. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum
23. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
24. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration
25. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum
26. French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)
27. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)
28. French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)
29. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration
30. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway
31. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)
32. Instauration du traitement adjuvant endovésical par épirubicine des tumeurs de vessie n’infiltrant pas le muscle : premier retour national d’expérience du CC-AFU vessie
33. Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG
34. Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria
35. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment
36. Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels
37. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study
38. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer
39. Cistoprostatectomia totale con o senza uretrectomia laparotomica
40. Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstruction
41. Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature)
42. BCG-thérapie, quelle surveillance ?
43. Cistoprostatectomía total con o sin uretrectomía por laparotomía
44. Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study
45. Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies
46. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : tumeurs de la vessie
47. Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study
48. Surveillance active du cancer de prostate : survie sans traitement curatif selon critères d’éligibilité stricts ou élargis
49. La sarcopénie est-elle un facteur de morbi-mortalité dans le traitement des tumeurs localisées de la vessie infiltrant le muscle ?
50. Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.